DBV TECHNOLOGIES
DBV Technologies is a global clinical stage biopharmaceutical company founded by pediatricians and entrepreneurs who believed that food allergies could one day be treated safely and effectively. With this mission driving their commitment to the advancement of treatments in this field, they are investigating a potential new class of immunotherapy that aims to activate the immune system of patients through the skin.
DBV TECHNOLOGIES
Industry:
Biopharma Biotechnology Health Care Health Diagnostics
Founded:
2002-01-01
Address:
Bagneux, Ile-de-France, France
Country:
France
Website Url:
http://www.dbv-technologies.com
Total Employee:
51+
Status:
Active
Contact:
+33 (0)1 55 42 78 78
Email Addresses:
[email protected]
Total Funding:
243.32 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Tag Manager WordPress Content Delivery Network Mobile Non Scaleable Content Euro IPv6 Yoast WordPress SEO Plugin JsDelivr
Similar Organizations
Bionanoplus
Bionanoplus focuses on the development of polymeric nanoparticles and microparticles as controlled release drug delivery systems.
Clinical Genomics Technologies
Clinical Genomics develops innovative products for colorectal cancer diagnosis.
Novavax
Novavax is a clinical-stage biotechnology company focused on the discovery and development of innovative vaccines.
PET-Technology
PET-Technology is a federal network of medical centers for the diagnosis and treatment of cancer and the production of radiopharmaceuticals.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
Braidwell
Braidwell investment in Post-IPO Equity - DBV Technologies
Venrock Healthcare Capital Partners
Venrock Healthcare Capital Partners investment in Post-IPO Equity - DBV Technologies
Bpifrance
Bpifrance investment in Post-IPO Equity - DBV Technologies
Baker Brothers Advisors LLC
Baker Brothers Advisors LLC investment in Post-IPO Equity - DBV Technologies
RA Capital Management
RA Capital Management investment in Post-IPO Equity - DBV Technologies
Fairmount Funds Management
Fairmount Funds Management investment in Post-IPO Equity - DBV Technologies
Vivo Capital
Vivo Capital investment in Post-IPO Equity - DBV Technologies
Alto Invest
Alto Invest investment in Series C - DBV Technologies
Lundbeckfonden Ventures
Lundbeckfonden Ventures investment in Series C - DBV Technologies
ALK Abelló
ALK Abelló investment in Series C - DBV Technologies
Key Employee Changes
| Date | New article |
|---|---|
| 2020-02-06 | DBV Technologies Announces Appointment of Pascal Wotling as Chief Technical Operations Officer |
Official Site Inspections
http://www.dbv-technologies.com Semrush global rank: 2.15 M Semrush visits lastest month: 9.32 K
- Host name: cloudproxy10055.sucuri.net
- IP address: 192.124.249.55
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
